These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 38996818)
1. Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review. Griskaitis M; Thielemann I; Schönfeld V; Falman A; Scholz S; Reinacher U; Haas L; Wichmann O; Harder T J Infect; 2024 Sep; 89(3):106228. PubMed ID: 38996818 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines. Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033 [TBL] [Abstract][Full Text] [Related]
3. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial. van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575 [TBL] [Abstract][Full Text] [Related]
4. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers. Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180 [TBL] [Abstract][Full Text] [Related]
6. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children. Vesikari T; Forsten A; Laudat F; Li P; Van Der Wielen M; Hezareh M; Perez JL; Webber C Vaccine; 2020 May; 38(22):3902-3908. PubMed ID: 32284274 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth. Warshaw MG; Siberry GK; Williams P; Decker MD; Jean-Philippe P; Lujan-Zilbermann J J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e69-e74. PubMed ID: 28339668 [TBL] [Abstract][Full Text] [Related]
8. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132 [TBL] [Abstract][Full Text] [Related]
10. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Khatami A; Snape MD; Davis E; Layton H; John T; Yu LM; Dull PM; Gill CJ; Odrjlin T; Dobson S; Halperin SA; Langley JM; McNeil SA; Pollard AJ Vaccine; 2012 Apr; 30(18):2831-8. PubMed ID: 22394992 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599 [TBL] [Abstract][Full Text] [Related]
12. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination. van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957 [TBL] [Abstract][Full Text] [Related]
13. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564 [TBL] [Abstract][Full Text] [Related]
14. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine. van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial. Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870 [TBL] [Abstract][Full Text] [Related]
16. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy. Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504 [TBL] [Abstract][Full Text] [Related]
17. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease. Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566 [TBL] [Abstract][Full Text] [Related]
18. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool. Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925 [TBL] [Abstract][Full Text] [Related]
19. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial. Baxter R; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M Pediatr Infect Dis J; 2015 Nov; 34(11):1236-43. PubMed ID: 26237742 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]